Edition:
United States

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

141.90USD
25 Sep 2018
Change (% chg)

-- (--)
Prev Close
$141.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
243,560
52-wk High
$236.05
52-wk Low
$119.90

Latest Key Developments (Source: Significant Developments)

Bluebird Bio Reports Q4 Loss Per Share $2.52‍​
Wednesday, 21 Feb 2018 04:05pm EST 

Feb 21 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q4 REVENUE $4.2 MILLION VERSUS $1.6 MILLION.‍ENDED YEAR WITH $1.6 BILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES​.QTRLY LOSS PER SHARE $2.52‍​.  Full Article

Bluebird Bio Expects Three Regulatory Filings By End 2019
Tuesday, 9 Jan 2018 10:50am EST 

Jan 9 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO CEO SAYS EXPECTS THREE REGULATORY FILINGS BY END 2019.BLUEBIRD SEES FILING FOR APPROVAL IN BETA THALASSEMIA IN 2018.BLUEBIRD BIO SEES FILING FOR US AND EU APPROVAL OF B2121 FOR MULTIPLE MYELOMA IN 2019.  Full Article

Bluebird Bio Prices Public Offering Of 3.2 Mln Shares At $185/Share
Tuesday, 12 Dec 2017 08:46pm EST 

Dec 12 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.‍PRICED UNDERWRITTEN PUBLIC OFFERING OF 3.2 MILLION SHARES OF ITS COMMON STOCK AT $185 PER SHARE​.  Full Article

Bluebird Bio Announces Proposed Public Offering Of Common Stock
Monday, 11 Dec 2017 04:01pm EST 

Dec 11 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.BLUEBIRD BIO INC - HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $600 MILLION OF ITS COMMON STOCK.  Full Article

bluebird bio And TC BioPharm Announce Strategic Collaboration
Thursday, 7 Dec 2017 08:00am EST 

Dec 7 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO AND TC BIOPHARM ANNOUNCE STRATEGIC COLLABORATION TO RESEARCH AND DEVELOP GAMMA DELTA CAR T CELL PRODUCT CANDIDATES FOR CANCER IMMUNOTHERAPY.BLUEBIRD BIO INC - FINANCIAL TERMS OF AGREEMENT INCLUDE A $16 MILLION UPFRONT PAYMENT.BLUEBIRD BIO - FINANCIAL TERMS OF AGREEMENT ALSO INCLUDE POTENTIAL RESEARCH AND DEVELOPMENT, COMMERCIAL MILESTONE PAYMENTS.BLUEBIRD BIO - AS PART OF DEAL, TC BIOPHARM ALSO ELIGIBLE TO GET UNDISCLOSED TIERED ROYALTIES ON PRODUCT SALES.BLUEBIRD BIO INC - CO, TC BIOPHARM WILL WORK TOGETHER TO ADVANCE TC BIOPHARM'S LEAD CAR-ENGINEERED GAMMA DELTA T CELL PROGRAM INTO CLINICAL TRIALS.  Full Article

Bluebird Bio Acquires Manufacturing Facility In North Carolina
Wednesday, 29 Nov 2017 08:00am EST 

Nov 29 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO ACQUIRES MANUFACTURING FACILITY IN NORTH CAROLINA AND EXECUTES MULTIPLE GLOBAL SUPPLY AGREEMENTS TO ENHANCE ABILITY TO DELIVER GENE THERAPIES TO PATIENTS.  Full Article

Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA
Thursday, 16 Nov 2017 08:30am EST 

Nov 16 (Reuters) - Celgene Corp :Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA and prime eligibility from EMA for relapsed and refractory multiple myeloma.Celgene Corp - ‍designations based on preliminary clinical data from ongoing phase i study of bb2121 in heavily pre-treated multiple myeloma​.Celgene Corp - ‍updated data from CRB-401 is scheduled to be presented at 59(th) annual meeting of american society of hematology in Atlanta​.  Full Article

bluebird bio reports qtrly ‍loss per share $1.73​
Wednesday, 1 Nov 2017 07:30am EDT 

Nov 1 (Reuters) - bluebird bio Inc :bluebird bio reports third quarter 2017 financial results and recent operational progress.Q3 revenue $7.7 million versus I/B/E/S view $7.1 million.bluebird bio Inc qtrly ‍loss per share $1.73​.Q3 earnings per share view $-1.71 -- Thomson Reuters I/B/E/S.  Full Article

Bluebird Bio Inc initiates ‍expansion cohort of CRB-401 Phase 1 study of bb2121
Wednesday, 13 Sep 2017 08:00am EDT 

Sept 13 (Reuters) - bluebird bio Inc :bluebird bio Inc - ‍expansion cohort of crb-401 phase 1 study of bb2121, an anti-BCMA CAR T therapy, has been initiated​.bluebird bio Inc - ‍bluebird bio and Celgene Corp are jointly developing bb2121​.  Full Article

Bluebird Bio Q2 net loss per share $1.73
Wednesday, 2 Aug 2017 04:05pm EDT 

Aug 2 (Reuters) - Bluebird Bio Inc :Bluebird Bio reports second quarter 2017 financial results and recent operational progress.Q2 revenue $16.7 million versus $1.6 million.Q2 revenue view $5.2 million -- Thomson Reuters I/B/E/S.Bluebird Bio sees that cash, cash equivalents & marketable securities of $1.2 billion as of June 30, 2017 will be sufficient to fund current operations into 2020.Qtrly net loss per share $1.73.Q2 earnings per share view $-1.65 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-FDA Grants Breakthrough Therapy Designation To Lenti-D For The Treatment Of Cerebral Adrenoleukodystrophy

* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO LENTI-D™ FOR THE TREATMENT OF CEREBRAL ADRENOLEUKODYSTROPHY